

## Auris Medical News Release

### Auris Medical to Present at the JMP Securities Life Sciences Conference 2015 on Wednesday, June 24

Zug, Switzerland, June 17, 2015 – Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that Thomas Meyer, Ph.D., Chairman and CEO, will present at the JMP Securities Life Sciences Conference 2015 on Wednesday, June 24, 2015, at 10:30 a.m. EDT, at the St. Regis Hotel in New York. A live webcast of the presentation will be available through the Events and Presentations page in the Investors section of the Company's website ([www.aurismedical.com](http://www.aurismedical.com)).

#### About Auris Medical

Auris Medical is a Swiss biopharmaceutical company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology. The Company is currently focusing on the development of treatments for acute inner ear tinnitus (AM-101) and for acute inner ear hearing loss (AM-111) by way of intratympanic injection with biocompatible gel formulations. In addition, Auris Medical is pursuing early-stage research and development projects. The Company was founded in 2003 and is headquartered in Zug, Switzerland.